Boskos Christos, Feuvret Loic, Noel Georges, Habrand Jean-Louis, Pommier Pascal, Alapetite Claire, Mammar Hamid, Ferrand Regis, Boisserie Gilbert, Mazeron Jean-Jacques
Institut Curie, Centre de Protonthérapie d'Orsay, Campus Universitaire, Orsay, France.
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406. doi: 10.1016/j.ijrobp.2008.10.053. Epub 2009 Feb 7.
To evaluate retrospectively the efficacy of conformal fractionated radiotherapy combining proton and photon beams after primary surgery for treatment of atypical and malignant meningiomas.
Between September 1999 and October 2006, 24 patients (12 male, 12 female) with histopathologically proven meningioma (atypical 19, malignant 5) received postoperative combined radiotherapy with a 201-MeV proton beam at the Centre Protontherapie d'Orsay and a high-energy photon beam. Six patients underwent gross total resection and 18 a subtotal resection. Median gross tumor volume and clinical target volume were 44.7 cm(3) and 153.3 cm(3), respectively. Mean total irradiation dose was 65.01 CGE (cobalt gray equivalent), with a mean proton total dose of 34.05 CGE and a mean photon total dose 30.96 CGE.
The median (range) follow-up interval was 32.2 (1-72) months. The overall mean local relapse-free interval was 27.2 (10-50) months, 28.3 (10-50) months for atypical meningioma and 23 (13-33) months for malignant meningioma. Ten tumors recurred locally. One-, 2-, 3-, 4-, 5-, and 8- year local control rates for the entire group of patients were 82.9% +/- 7.8%, 82.9% +/- 7.8%, 61.3% +/- 11%, 61.3% +/- 11%, 46.7% +/- 12.3%, and 46.7% +/- 12.3%, respectively. One-, 2-, 3-, 4-, 5-, and 8- year overall survival rates were 100%, 95.5% +/- 4.4%, 80.4% +/- 8.8%, 65.3% +/- 10.6%, 53.2% +/- 11.6%, and 42.6% +/- 13%, respectively. Survival was significantly associated with total dose. There was no acute morbidity of radiotherapy. One patient developed radiation necrosis 16 months after treatment.
Postoperative combination of conformal radiotherapy with protons and photons for atypical and malignant meningiomas is a well-tolerated treatment producing long-term tumor stabilization.
回顾性评估初次手术后采用质子束和光子束适形分割放疗治疗非典型和恶性脑膜瘤的疗效。
1999年9月至2006年10月期间,24例经组织病理学证实为脑膜瘤(非典型19例,恶性5例)的患者(男12例,女12例)在奥赛质子治疗中心接受了术后联合放疗,使用201 MeV质子束和高能光子束。6例患者接受了肿瘤全切除,18例接受了次全切除。肿瘤总体积中位数和临床靶体积分别为44.7 cm³和153.3 cm³。平均总照射剂量为65.01 CGE(钴灰当量),质子平均总剂量为34.05 CGE,光子平均总剂量为30.96 CGE。
中位(范围)随访时间为32.2(1 - 72)个月。总体平均局部无复发生存期为27.2(10 - 50)个月,非典型脑膜瘤为28.3(10 - 50)个月,恶性脑膜瘤为23(13 - 33)个月。10例肿瘤出现局部复发。全组患者1年、2年、3年、4年、5年和8年的局部控制率分别为82.9%±7.8%、82.9%±7.8%、61.3%±11%、61.3%±11%、46.7%±12.3%和46.7%±12.3%。1年、2年、3年、4年、5年和8年的总生存率分别为100%、95.5%±4.4%、80.4%±8.8%、65.3%±10.6%、53.2%±11.6%和42.6%±13%。生存率与总剂量显著相关。放疗无急性并发症。1例患者在治疗后16个月出现放射性坏死。
非典型和恶性脑膜瘤术后采用质子和光子适形放疗联合治疗耐受性良好,可实现长期肿瘤稳定。